J S Lazo
About
In The Last Decade
J S Lazo
19 papers receiving 774 citations
Peers
Comparison fields: 5 of 83
- Nutrition and Dietetics 326
- Molecular Biology 322
- Health, Toxicology and Mutagenesis 200
- Oncology 171
- Hematology 96
Countries citing papers authored by J S Lazo
This map shows the geographic impact of J S Lazo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J S Lazo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J S Lazo more than expected).
Fields of papers citing papers by J S Lazo
This network shows the impact of papers produced by J S Lazo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J S Lazo. The network helps show where J S Lazo may publish in the future.
Co-authorship network of co-authors of J S Lazo
This figure shows the co-authorship network connecting the top 25 collaborators of J S Lazo. A scholar is included among the top collaborators of J S Lazo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J S Lazo. J S Lazo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 23 | |
| 3 | Bleomycin. | 5 |
| 4 | Bleomycin. | 1 |
| 5 | 61 | |
| 6 | Bleomycin. | 5 |
| 7 | 104 | |
| 8 | Metallothionein localization and cisplatin resistance in human hormone-independent prostatic tumor cell lines. | 56 |
| 9 | 204 | |
| 10 | 50 | |
| 11 | 12 | |
| 12 | 54 | |
| 13 | Synthesis and evaluation of fluoromycin: a novel fluorescence-labeled derivative of talisomycin S10b. | 5 |
| 14 | In vivo circumvention of human colon carcinoma resistance to bleomycin. | 14 |
| 15 | 64 | |
| 16 | 51 | |
| 17 | 11 | |
| 18 | 17 | |
| 19 | 38 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.